Seelos Therapeutics Inc

Seelos Therapeutics Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.90
  • Today's Change-0.077 / -7.85%
  • Shares traded1.61k
  • 1 Year change+24.57%
  • Beta1.7365
Data delayed at least 15 minutes, as of Jun 07 2023 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing programs include SLS-004, SLS-006, and SLS-007.

  • Revenue in USD (TTM)808.00k
  • Net income in USD-72.96m
  • Incorporated1987
  • Employees16.00
  • Location
    Seelos Therapeutics Inc300 PARK AVENUE, 2ND FLOORNEW YORK 10022United StatesUSA
  • Phone+1 (646) 293-2100
  • Fax+1 (858) 436-8155
  • Websitehttps://seelostherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Medicinova Inc0.00-13.60m106.44m13.00--1.57-----0.2773-0.27730.001.380.00----0.00-17.51-17.37-18.18-17.97-------1,626.60----0.00---100.00---38.83------
Anixa Biosciences Inc0.00-12.09m107.62m4.00--3.87-----0.3958-0.39580.000.89870.00----0.00-38.54-80.77-39.42-85.60-------3,362.83----0.00---100.00---4.95------
Eyenovia Inc0.00-26.41m107.93m41.00--6.82-----0.7485-0.74850.000.41620.00----0.00-76.01-83.43-97.43-122.63-------618.56---16.750.3726---100.00---119.21--121.09--
Veru Inc21.28m-138.85m108.87m233.00--6.03--5.11-1.73-1.730.26460.20240.17511.273.4591,350.17-114.25-30.72-152.05-37.9558.1173.21-652.37-68.790.9074--0.4099---35.7623.58-1,232.97--40.58--
Seelos Therapeutics Inc808.00k-72.96m109.63m16.00------135.68-0.6779-0.67790.0075-0.16960.0171----53,866.67-154.69-168.03-324.26-259.48-----9,030.20-56,910.13-------------11.33------
Moolec Science SA0.00-602.87k109.68m----2.12-----0.0339-0.03390.001.380.00-------0.7234---0.7463--------------0.0554-------579.78------
Decibel Therapeutics Inc0.00-62.29m109.82m68.00--1.57-----2.49-2.490.002.790.00----0.00-43.83---51.28--------------0.00-------16.39------
Alaunos Therapeutics Inc2.92m-37.99m112.78m34.00--3.82--38.60-0.1703-0.17030.01310.12260.0437----85,941.18-56.86-69.23-79.70-81.33-----1,300.14-10,599.25---10.780.2713--634.17-14.4852.09---21.77--
Nektar Therapeutics88.83m-414.82m113.92m216.00--0.473--1.28-2.21-2.210.47281.270.1121.315.35411,236.10-52.32-14.82-58.40-16.3773.6893.24-467.00-66.227.86-9.280.00---9.67-21.4429.71---10.12--
CytomX Therapeutics Inc59.53m-78.74m114.10m116.00------1.92-1.20-1.200.9026-1.310.224--56.53513,146.60-29.63-23.82-56.77-32.06-----132.29-141.28--------42.48-5.7914.29--2.22--
Pardes Biosciences Inc0.00-93.00m114.18m57.00--0.6735-----1.58-1.580.002.750.00----0.00-43.13---45.24--------------0.00-------150.88------
Cidara Therapeutics Inc83.17m-8.99m114.33m73.00--4.26--1.37-0.1647-0.16471.000.29811.21--4.811,139,301.00-12.13-70.43-23.99-120.17-----9.99-166.50----0.00--29.69--29.83---17.35--
AN2 Therapeutics Inc0.00-48.62m114.81m35.00--1.39-----2.51-2.510.004.250.00----0.00-45.96---49.13--------------0.00-------52.46------
Data as of Jun 07 2023. Currency figures normalised to Seelos Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

15.63%Per cent of shares held by top holders
HolderShares% Held
Tontine Associates LLCas of 31 Mar 20235.07m4.22%
The Vanguard Group, Inc.as of 31 Mar 20234.98m4.15%
BlackRock Fund Advisorsas of 31 Mar 20231.65m1.37%
Horizons ETFs Management (Canada), Inc.as of 31 Mar 20231.44m1.20%
Geode Capital Management LLCas of 31 Mar 20231.14m0.95%
Uniplan Investment Counsel, Inc.as of 31 Mar 20231.13m0.94%
Wealth Effects LLCas of 31 Mar 2023956.05k0.80%
MAI Capital Management LLCas of 31 Mar 2023927.42k0.77%
Modera Wealth Management LLCas of 31 Mar 2023871.51k0.73%
Millennium Management LLCas of 31 Mar 2023624.86k0.52%
More ▼
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.